Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Antigen presentation and recognition by immune cells is not a single molecular target, but rather a critical immunological process in which antigen-presenting cells (APCs) display pieces of protein (antigens), typically bound to MHC molecules, on their surface for recognition by T cell receptors (TCRs) on T lymphocytes[1][2][3][6][7]. Professional APCs—such as dendritic cells, macrophages, and B cells—specialize in presenting antigens via MHC class II to helper T cells (CD4+), while all nucleated cells can present intracellular antigens via MHC class I to cytotoxic T cells (CD8+)[1][2][4][5][8]. This process is essential for initiating adaptive immune responses against pathogens and cancer, but can also be involved in autoimmunity and immune evasion by tumors and certain pathogens[6][7]. The phrase itself refers to an immunological pathway, not a discrete receptor or molecule, so it is not considered a direct therapeutic target in the way that a receptor, enzyme, or transporter would be.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antigen-presenting cell and antigen recognition process (APC (for Antigen-presenting cell); no canonical abbreviation for the process itself).